Rivaroxaban Versus Standard of Care for Patients With Excessive Atrial Ectopy or Short Atrial Runs and High Embolism Risk

The primary objective of the Short Run AF study is to evaluate the efficacy and safety of long term anticoagulation with rivaroxaban against standard of care (SOC) in patients with ESVEA and CHA2DS2VASC score ≥3 on the incidence of ischemic stroke and peripheral embolism after 2 years follow-up and the occurrence of major bleeding events. The primary efficacy endpoint is the first ischemic stroke or peripheral embolism detected clinically and on systematic cerebral MRIs in a time-to-event analysis. The primary safety outcome is major bleeding at any site in the body according to the criteria of the International Society of Thrombosis and Hemostasis (ISTH)(23-25).

NCT Number	NCT05487950
Lead Sponsor	Assistance Publique - Hôpitaux de Paris
Conditions	Excessive Supraventricular Ectopies or Short Atrial Runs (ESVEA)
Enrollment	550 participants
Start Date	2023-04-05
Primary Completion	2027-04-05 (estimated)
Study Completion	2027-04-05 (estimated)
Updated on ClinicalTrials.gov	2023-03-28